RNA interference (RNAi), today announced that it has entered into a delivery collaboration with Dainippon Sumitomo Pharma Co., Ltd. of Japan to demonstrate the functional delivery of Silence's proprietary siRNA molecules to specific targets.
Silence Therapeutics has developed AtuRNAi, a novel proprietary short interfering RNA (siRNA) molecule which is chemically modified to improve stability, reduce manufacturing costs and increase yield. The collaboration will also make use of Silence's AtuPLEX delivery technology, which has been shown to improve functional intracellular uptake. Iain Ross, chairman and chief executive of Silence Therapeutics, said:
"We are delighted to have signed this agreement with Dainippon Sumitomo Pharma, which further underscores the potential of Silence's science and delivery technology. We anticipate that the initial collaboration will lead to a substantive relationship between our companies."
Dr. Keiichi Ono, senior executive officer and executive director of drug research division of Dainippon Sumitomo Pharma, said:
"Following extensive due diligence in the sector, we have chosen to partner with Silence Therapeutics because of the company's proven ability in the delivery of siRNA molecules and the depth of its experience in this area. We look forward to expanding this collaboration further in the future."
Financial details have not been disclosed.
Silence Therapeutics has been advised by Summit Pharmaceuticals International which represents and markets the technologies, products and expertise of Silence Therapeutics in Japan.
Want to read more?
Thermo Fisher Scientific Establishes RNAi Discovery Grant Program
Inovio Biomedical to Present at Novel Vaccines: Design & Development
